Defence's has tested 43 AccumTM variants conjugated to T-DM1 with a low conjugation ratio (1- 4 AccumTM per T-DM1) in order to select the best ones to pursue our selection of the optimized Accum-T-DM1 conjugate based on in vitro assessments. These studies highlight the additive effect of the AccumTM technology and guide the selection of the optimal Accum-T-DM1 in vivo testing on breast and gastric cancer models. On the 43 AccumTM variants tested, we have selected the 8 best which will be sent this week to our collaborator at the
'The 8 selected AccumTM variants produced very impressive results that confirms the strength and optimization of our AccumTM platform in the ADC field of therapeutics against breast and gastric cancer. The versatility of our AccumTM platform and variants gives us a solid competitive advantage' said
About Defence
Contact:
President
CEO and Director
P: (514) 947-2272
E: Splouffe@defencetherapeutics.com
WEB: www.defencetherapeutics.com
Cautionary Statement Regarding 'Forward-Looking' Information
This release includes certain statements that may be deemed 'forward-looking statements'. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
(C) 2021 Electronic News Publishing, source